Chinese Red Yeast Rice Inhibition of Prostate Tumor Growth in SCID Mice

Mee Young Hong1, Susanne Henning1, Aune Moro1, Navindra P. Seeram2, Yanjun Zhang1, and David Heber1

Abstract

Prostate cancer is a slowly developing but very common cancer in males that may be amenable to preventive strategies that are not toxic. Chinese red yeast rice (RYR), a food herb made by fermenting Monascus purpureus Went yeast on white rice, contains a mixture of eight different monacolins that inhibit cholesterologenesis in addition to red pigments with antioxidant properties. Monacolin K is identical to lovastatin (LV), but LV unlike RYR can be used in individuals intolerant to statins due to muscle pain. Both LV and RYR inhibit de novo cholesterologenesis, which is critical to the growth of tumor cells. Long-term use of statin drugs has been associated with a reduced risk of prostate cancer. We have previously shown that RYR inhibited androgen-dependent and androgen receptor–overexpressing androgen-independent prostate cancer cell proliferation in vitro. This study was designed to determine whether RYR and LV inhibit prostate tumor growth in SCID mice. RYR significantly reduced tumor volumes of androgen-dependent and androgen-independent prostate xenograft tumors compared with animals receiving vehicle alone (P < 0.05). Inhibition by RYR was greater than that observed with LV at the dose found in RYR, showing that other compounds in RYR contributed to the antiproliferative effect. There was a significant correlation of tumor volume to serum cholesterol (P < 0.001). RYR decreased gene expression of androgen synthesizing enzymes (HSD3B2, AKR1C3, and SRD5A1) in both type of tumors (P < 0.05). Clinical studies of RYR for prostate cancer prevention in the increasing population of men undergoing active surveillance should be considered. Cancer Prev Res; 4(4); 608–15. ©2011 AACR.

Introduction

Prostate cancer is the second most common cause of cancer death in men in the United States today (1). It is estimated that 217,730 new cases occurred and 32,050 men will die of prostate cancer in 2010 (1). Early-stage prostate cancer is androgen-dependent and can be effectively treated by androgen ablation therapy, radiation, and/or surgery (2–7). However, prostate tumors relapse and advance to an androgen-independent state where they progress, in the absence of circulating testosterone, leading to metastasis and death (2–7). Reducing the rate of emergence of androgen-independent cells in late stages of advanced prostate cancer is critical to reducing overall mortality from prostate cancer.

Red yeast rice (RYR) is a traditional food spice consumed throughout Asia (8–11) and its food and medicinal value is believed to date back more than a thousand years. RYR contains a family of monacolins, one of which is monacolin K, which is identical to lovastatin (LV), and has the ability to inhibit cholesterol synthesis and lower plasma cholesterol levels (12, 13). Our group showed that the administration of a dose of 2,400 mg/day of RYR, containing 0.4% monacolins by weight, to hypercholesterolemic participants resulted in significant reduction of total cholesterol and low-density lipoprotein (LDL) cholesterol with approximate bioequivalence to 20 mg of LV, suggesting that other substances in RYR had biological activity (14).

A recent case–control study (15) reported that hypercholesterolemia was associated with a 50% increase in the risk of prostate cancer. In clinical studies, statin drug use was protective against prostate cancer (16–24) although the mechanisms of this effect have not been established. Recently, we showed that RYR could inhibit in vitro proliferation of both LNCaP human prostate cancer cells and LNCaP-AR cells which are androgen-independent and overexpress the androgen receptor (AR; ref. 25).

Androgen-independent cells synthesize testosterone intracellularly via several enzymes which support tumor growth in the absence of circulating androgens (26–30).
3β-Hydroxysteroid dehydrogenase type 2 (HSD3B2) catalyzes the conversion of dehydroepiandrosterone to androstenedione (26, 27). In addition, aldo-keto reductase family 1, member C3 (AKR1C3) converts androstenedione to testosterone, and increased amounts of AKR1C3 have been shown in prostate cancer cells (28). Testosterone is converted to dihydrotestosterone (DHT) by steroid 5α-reductase type 1 (SRD5A1; ref. 29). Because DHT has a greater affinity for AR than testosterone, it has been proposed that DHT is critical to prostate cancer development (27). Inhibitors of SRD5A1, such as finasteride, reduce prostate size and have been shown to reduce the development of prostate cancers by 25% but increase the number of advanced cancers found (31, 32). Therefore, androgen synthesis enzymes may be critical for the development of androgen-independent prostate cancer.

This study examined the effects of RYR on the growth of androgen-dependent LNCaP and androgen-independent LNCaP-AR human prostate cancer xenografts in severe combined immunodeficient (SCID) mice as well as the relationship of circulating cholesterol to tumor growth and the effects of treatment with RYR on gene expression of androgen-synthesizing enzymes.

Materials and Methods

SCID animals and diets

Sixty male SCID mice, ages 5 weeks, were purchased from Taconic Farms Inc. and housed 5 mice per cage in a pathogen-free environment. After acclimation, all mice were implanted in the shoulder with androgen-dependent LNCaP or androgen-independent LNCaP-AR human prostate cancer cells (8 × 10⁶) subcutaneously (n = 30 each). LNCaP cells were purchased from the American Type Culture Collection and lower passages (4–6 passages) of cells were used. LNCaP-AR cells were provided from Dr. Charles Sawyers’ lab (University of California, Los Angeles, CA) 3 months prior to the experiments. LNCaP cells are androgen-dependent prostate cancer cells, whereas LNCaP-AR cells are androgen-independent prostate cancer cells with AR overexpression. The LNCaP and LNCaP-AR cells were authenticated by Pathogen PCR Testing in Division of Laboratory Animal Medicine (DLAM Lab, University of California, Los Angeles, CA) right before the xenograft study.

In each xenograft tumor group (LNCaP and LNCaP-AR), 10 mice were assigned to each diet treatment (control, LV, or RYR diet). The control diet was a modified AIN 93G diet (Dyets) with 20% fat (20% soybean oil). The RYR diet contained 5% of RYR powder (Botanica Bioscience) with the modified AIN93G diet. For LV diet, LV (Mylan Pharmaceuticals Inc.) was added to the control diet in an amount equivalent to that in the 5% RYR diet. The amounts present in the LV diet and 5% RYR diet were found to be nearly identical after determination by high-performance liquid chromatography (HPLC; Fig. 1). Statin standard was used as a positive control to identify the statin (monacolin K) component in RYR by using HPLC (Fig. 1).

Animal weight, food intake, and tumor volume were measured weekly. The tumor volume was calculated by the formula: length × width × height × 0.5236 (ref. 33). At sacrifice, primary tumors were excised and blood was...
collected through cardiac puncture. The animal protocol was approved by Animal Care Committee of the University of California, Los Angeles.

Serum cholesterol and PSA

Serum cholesterol concentrations were determined by cholesterol enzymatic methods by using a cholesterol standard (StanBio). Serum prostate-specific antigen (PSA) was measured with a PSA ELISA kit (Diagnostic Systems Laboratories) according to the manufacturer’s protocol.

In situ cell proliferation and apoptosis

Paraformaldehyde-fixed and paraffin-embedded tumor tissues were used to determine in situ cell proliferation and apoptosis analysis. Proliferating cells were detected by using monoclonal Ki-67 antibody (BD Biosciences; refs. 34, 35). Total number of cells and stained proliferating cells were counted in 2 subsquares in a 4 × 4 grid in 10 microscopic areas. Data are expressed as proliferation index (%), which was calculated by the formula: (no. of proliferating cells in one grid/total number of cells in one grid) × 100. Apoptosis assay was based on terminal deoxynucleotidyl transferase-mediated dUTP-biotin nick end labeling (Millipore; ref. 34). Apoptotic cells were counted in 15 microscopic fields and data are expressed in number of apoptotic cells/field.

RNA extraction and reverse transcription

Total RNA was extracted by using TRIZOL reagent (Invitrogen) and quantified by measuring the absorbance at 260 nm with a Gene Quant Spectrophotometer (Amersham-Pharmacia Biotech). Reverse transcription was performed on 3 μg of RNA by using oligo(dT)12-18 primers (Invitrogen) with SuperScript III reverse transcriptase (Invitrogen) according to the manufacturer’s instructions.

Quantitative real-time PCR

Gene expressions were determined by Taqman Universal PCR master mix and primers (Applied Biosystems) by quantitative real-time PCR, using the ABI 7900 HT Sequence Detector (Applied Biosystems; ref. 36). The transcription levels of target genes were normalized to r18S expression. Every set of reverse transcription reactions contains a reverse transcription negative control (no RNA thus no PCR products) to confirm that no contamination or anomaly has occurred.

Statistics

Data were analyzed by 1-way ANOVA followed by Student–Newman–Keuls multiple comparison with GraphPad PRISM 3.0 (GraphPad Software) in separate androgen-dependent and -independent SCID sets. The comparison between LNCaP and LNCaP-AR were done

Figure 2. A, RYR effects on SCID tumor volume. RYR-fed mice significantly reduced androgen-dependent and -independent tumor compared with control diet-fed mice. B, RYR effects on in situ cell proliferation. Proliferation index was lower in RYR group in both androgen-dependent and -independent SCID tumors. Values are mean ± SE. *, significantly different from control at P < 0.05.
by using t-test. The relationship between tumor volume and serum cholesterol levels was analyzed by correlation and a linear regression model.

Results

SCID Tumor volume
RYR significantly reduced androgen-dependent and -independent tumor volumes compared with control by 54% and 41%, respectively ($P < 0.05$; Fig. 2A). LV also decreased tumor volume by 32% ($P < 0.05$) but only in androgen-dependent SCID animals, and to a lesser degree than those receiving RYR (Fig. 2A).

In situ cell proliferation and apoptosis
Proliferation index was lower in the RYR group in both androgen-dependent and -independent SCID tumors by 32% and 47% ($P < 0.05$; Fig. 2B). There was no significant effect of RYR or LV on apoptosis (data not shown).

Serum PSA
PSA is a risk marker of prostate cancer and is often elevated in the presence of prostate cancer. RYR decreased serum PSA levels compared with control in both LNCaP- and LNCaP-AR-injected SCID animals ($P < 0.05$; Fig. 3).

Serum cholesterol and HMGCR gene expression
RYR decreased serum cholesterol levels by 20% in animals with androgen-dependent tumors, and 30% in animals with androgen-independent tumors ($P < 0.05$; Fig. 4A).
In animals treated with the LV diet, serum cholesterol levels declined by 10% in animals with androgen-dependent tumors, but not in those with androgen-independent tumors ($P < 0.05$; Fig. 4A). The RYR diet downregulated 3-hydroxy-3-methyl-glutaryl CoA reductase (HMGCR) gene expression by 60% in animals with androgen-dependent tumors and 40% in animals with androgen-independent tumors ($P < 0.05$; Fig. 4B). In contrast, LV-treated animals had a 4-fold increase in HMGCR gene expression compared with animals receiving the control diet (Fig. 4B). There was a strong positive correlation between tumor volume and serum cholesterol levels ($R^2 = 0.6571$, $P < 0.001$; Fig. 5).

Gene expression of androgen synthesizing enzymes and androgen receptor
In RYR-fed animals, HSD3B2, AKR1C3, and SRD5A1 gene expression was downregulated more than 3-fold in LNCaP tumors, and more than 2-fold in LNCaP-AR tumors ($P < 0.05$; Fig. 6A–C). The RYR diet also decreased AR expression more than 2-fold in androgen-independent SCID tumors ($P < 0.05$). The transcription levels of HSD3B2, AKR1C3, and SRD5A1 and AR were higher in androgen-independent tumors than androgen-dependent tumors ($P < 0.05$; Figs. 6 and 7; Supplementary Data).

Discussion
Androgens are critical to prostate cancer development and to normal development, proliferation, and differentiation of prostate epithelial cells (2, 3). Androgen deprivation therapy is used after failure of primary prostate cancer, but the emergence of androgen-independent prostate cancer often occurs. Although cholesterogenesis is necessary for testosterone synthesis (30), there is no convincing evidence in humans that reducing cholesterol biosynthesis affects circulating testosterone levels (37). Cholesterol-rich membranes, generally referred to as "lipid rafts," exhibit a liquid-ordered structure and are insoluble in nonionic detergents. Lipid rafts sequester and exclude certain types of signaling proteins and are thought to act as membrane platforms for signal transduction. The depletion of cholesterol from the lipid raft could inhibit prostate tumor xenograft growth (38). On the contrary, cholesterol is a required intermediate for tumor cell growth, and reduction of circulating cholesterol levels may influence the risk of progression and biology of prostate cancer (39, 40). Although we and others (38) have seen a correlation between xenograft size and circulating cholesterol levels, further research is needed to clarify which of these mechanisms are most likely involved in tumor growth inhibition.

Figure 3. RYR effects on PSA levels. RYR administration reduced serum PSA levels compared with control in both types of SCID mice. Values are mean ± SE. * significantly different from control at $P < 0.05$. 

www.aacrjournals.org Cancer Prev Res; 4(4) April 2011 611
LNCaP tumors are extremely hematogenous, unlike human prostate cancer and most other xenograft models. Consequently, bioavailability of the active ingredient(s) in RYR with respect to the tumor is likely to be higher than that in the clinical situation. Therefore, it is possible that significant effects on intratumoral cholesterol might be achieved.

The mechanisms by which prostatic tissue maintains tissue androgens may include metabolism of adrenal androgens or de novo synthesis from cholesterol (41, 42). This study verified that higher cholesterol levels were strongly correlated with larger prostate tumors. RYR downregulated enzymes involved in androgen synthesis (HSD3B2, AKR1C3, and SRD5A1) and reduced cholesterol levels. RYR may decrease androgen synthesis by reducing the precursor (i.e., cholesterol) of androgen via the inhibition of de novo cholesterologenesis and downregulation of androgen synthesizing enzyme genes. In patients undergoing androgen deprivation therapy to treat prostate cancer, RYR could delay or reduce disease progression through effects on residual androgen production via reduction of the precursor of the androgen and downregulating gene expression of androgen synthesizing enzymes.

Androgen signaling occurs via intracellular AR (2, 3, 43). The AR has been implicated in the development and progression of recurrent prostate cancer and its expression is frequently upregulated in androgen-independent prostate cancer (44–46). This enhances the response to circulating androgens and those synthesized in the prostate cancer cell. This upregulation of the AR in androgen-independent tumors was consistent with our findings in which RYR downregulated AR transcription levels in the animals with androgen-independent tumors. Therefore, RYR may be particularly helpful in the subgroup of patients with androgen-independent prostate cancer and AR upregulation.

Figure 4. A, RYR effects on cholesterol levels. RYR reduced serum cholesterol levels more than 15% of control in androgen-dependent and -independent SCID mice. B, RYR effects on HMGCR gene expression. RYR downregulated HMGCR gene expression in both types of xenografted tumors. In contrast, lovastatin drug increased HMGCR gene expression in LNCaP xenograft animal. Values are mean ± SE. *, significantly different from control at $P < 0.05$.

Figure 5. Correlation between tumor volume and serum cholesterol levels. As tumors were getting bigger, serum cholesterol increased, or vice versa ($R^2 = 0.6571$, $P < 0.001$). All data were included.
De novo cholesterogenesis may be a key target for the prevention of the emergence of prostate cancer. Much convincing evidence indicates that tumors undergo deregulated cholesterogenesis mainly at the critical rate-controlling juncture (i.e., the reaction catalyzed by HMGCR). The mevalonate component of the cholesterol biosynthesis pathway plays a key role in controlling cell proliferation by generating prenyl intermediates, particularly farnesyl and geranyl–geranyl moieties (47–49). These isoprenoids covalently modify, and thus modulate, the biological activity of signal-transducing proteins, such as G-protein signaling.

We have previously shown the anticancer properties of RYR in human prostate cancer cell lines (25). The in vitro effects showed that RYR exhibited stronger inhibition of tumor cell growth compared with LV treatment in human androgen-dependent and -independent prostate cancer cells (25). The results are extended in the current in vivo

**Figure 6.** RYR effects on gene expression involved in androgen synthesis. RYR-fed animals downregulated HSD3B2 (A), AKR1C3 (B), and SRD5A1 (C) gene expression by more than 3- and 2-fold in LNCaP and LNCaP-AR SCID tumors. Values are mean ± SE. *, significantly different from control at $P < 0.05$.

**Figure 7.** RYR effects on gene expression of AR. RYR diet also decreased AR expression by more than 2-fold in androgen-independent SCID tumors. Values are mean ± SE. *, significantly different from control at $P < 0.05$. 

*De novo* cholesterogenesis may be a key target for the prevention of the emergence of prostate cancer. Much convincing evidence indicates that tumors undergo deregulated cholesterogenesis mainly at the critical rate-controlling juncture (i.e., the reaction catalyzed by HMGCR). The mevalonate component of the cholesterol biosynthesis pathway plays a key role in controlling cell proliferation by generating prenyl intermediates, particularly farnesyl and geranyl–geranyl moieties (47–49). These isoprenoids covalently modify, and thus modulate, the biological activity of signal-transducing proteins, such as G-protein signaling. Further studies are needed to determine the effects of RYR on isoprenoid metabolism and related signaling.

We have previously shown the anticancer properties of RYR in human prostate cancer cell lines (25). The *in vitro* effects showed that RYR exhibited stronger inhibition of tumor cell growth compared with LV treatment in human androgen-dependent and -independent prostate cancer cells (25). The results are extended in the current *in vivo*
xenograft study. It is also interesting that LV administration enhanced HMGCR gene expression in androgen-dependent tumors but RYR downregulated the transcription levels in both types of tumor. Uptregulation of LV on HMGCR has been reported as a feedback mechanism of lowering cholesterol. RYR contains other bioactive components such as pigments, sterols, isoflavones, and tannins. It is possible that the nonstatin ingredients in RYR may affect the different direction of response versus LV treatment. The advantage of using RYR over LV, which is a drug, is that RYR reduced tumor volume, PSA levels, and cholesterol levels without elevation of gene expression related to HMGCR, androgen synthesis, and inflammation. Moreover, RYR showed anticancer effects in both androgen-dependent and -independent prostate tumors whereas effects of LV were observed mainly in androgen-dependent SCID prostate tumors.

RYR contains red pigments and statin, and our previous experiment (36) showed that the pigments also show anticancer effects in cancer cells. Therefore, a matrix with other structural analogs and other substances including pigments was able to inhibit prostate tumor growth. Although our previous studies clearly showed that there are other factors beyond monacolin K mediating some of the effects of RYR, further studies are needed to determine the effects of other active components in RYR, including sterols, isoflavones, and tannins, on prostate cancer growth.

The amount of RYR typically used in clinical trials is 1,200 to 2,400 mg/day of RYR containing approximately 10 mg total monacolins, half of which is monacolin K.

This raises a question about function of the other monacolins and non-monacolin compounds in the products, as the monacolin K content is lower than the low end of what is usually considered effective for LV (10–80 mg/day). A meta-analysis published in 2006 cited 93 published, controlled clinical trials—91 published in Chinese. Compared with placebo results, total cholesterol decreased by 35 mg/dL, LDL cholesterol decreased by 28 mg/dL, triglycerides decreased by 35 mg/dL, and high-density lipoprotein (HDL) cholesterol increased by 6 mg/dL. (50). Of the clinical trials reviewed in the meta-analysis, the only study conducted in the United States was a randomized, placebo-controlled, double-blind study of subjects with primary hyperlipidemia (LDL > 160 mg/dL). At the end of 12 weeks, it reported changes compared with placebo of −35, −33, −13, and 0 mg/dL for total cholesterol, LDL, triglycerides, and HDL, respectively (14). Although RYR has shown inhibition of androgen-dependent and -independent prostate tumors in our studies, it is also likely to be better tolerated than statin drugs. In a recent study (51), patients experiencing myalgias, gastrointestinal intolerance, or elevated liver function tests with lipid-lowering drugs were able to tolerate RYR without any side effects. On the basis of our basic research and clinical observations of RYR in lipid-lowering trials, it is our view that clinical studies of RYR for prostate cancer prevention in men undergoing active surveillance should be considered.

Acknowledgments

We thank Dr. Simin Liu for allowing us to use his real-time PCR equipment.

Grant Support

This study was funded by UCLA/NCI Clinical Nutrition Research Unit Grant CA 42710 and by Grant W81XWH-07-1-0158 from Department of Defense (M.Y. Hong).

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received August 30, 2010; revised December 15, 2010; accepted January 14, 2011; published OnlineFirst January 28, 2011.

References

Chinese Red Yeast Rice and Prostate Cancer


Chinese Red Yeast Rice Inhibition of Prostate Tumor Growth in SCID Mice

Mee Young Hong, Susanne Henning, Aune Moro, et al.


Updated version
Access the most recent version of this article at:
doi:10.1158/1940-6207.CAPR-10-0219

Cited articles
This article cites 46 articles, 10 of which you can access for free at:
http://cancerpreventionresearch.aacrjournals.org/content/4/4/608.full#ref-list-1

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.